Health Care • Medical/Dental Instruments
$177.36 ▲ +4.56
(+2.64%)
MKT CAP: $91.65B • VOL: 2.50M
52W L $139 52W H $185
MMM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $24.95B | $24.57B | $24.61B |
| YoY Revenue Growth % | +1.5% | -0.1% | — |
| Gross Profit | $9.96B | $10.13B | $10.83B |
| Gross Margin % | 39.9% | 41.2% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $4.63B | $4.82B | -$10.69B |
| Operating Margin % | 18.6% | 19.6% | -43.4% |
| Net Income (GAAP) | $3.25B | $4.17B | -$7.00B |
| EBITDA (Normalized) | $5.36B | $5.77B | -$9.80B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $2.31B | $1.82B | $6.68B |
| Capital Expenditures (CapEx) | $910.0M | $1.18B | $1.11B |
| Free Cash Flow (FCF) | $1.40B | $638.0M | $5.57B |
| FCF Margin % | 5.6% | 2.6% | 22.6% |
| Return on Invested Capital (ROIC %) | 31.8% | 36.0% | -27.7% |
| Cash & Short-Term Equivalents | $4.15B | $4.39B | $5.54B |
| Total Debt (Short + Long Term) | $10.93B | $11.13B | $11.79B |
| Total Stockholders' Equity | $4.70B | $3.84B | $24.19B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MMM.